Advanced search
Start date

The prognostic value and biological role of overexpressed proteins in oral squamous cell carcinoma identified by mass spectrometry-based proteomic

Grant number: 17/26764-8
Support type:Scholarships in Brazil - Post-Doctorate
Effective date (Start): February 01, 2019
Effective date (End): January 31, 2021
Field of knowledge:Health Sciences - Dentistry
Principal Investigator:Ricardo Della Coletta
Grantee:Mauricio da Rocha Dourado
Home Institution: Faculdade de Odontologia de Piracicaba (FOP). Universidade Estadual de Campinas (UNICAMP). Piracicaba , SP, Brazil


Despite the improvement in the diagnosis and treatment of patients with oral squamous cell carcinoma (OSCC), the 5-year survival rate remains around 50-60%, without significant changes in the last decades. The treatment decision and patient's prognosis relies on clinical parameters (TNM system) and histopathological features, tools that have not been shown to be widely effective. In that sense, the identification, validation, and clinical implementation of new markers that would help in the treatment selection, and occasionally prove to be new therapeutic targets that also aid the prognosis prediction, is needed and urgent. The aim of this project is to select proteins that are promising markers to be used in patients with OSCC. For that, an initial selection was based on proteins lists originated in previous studies from our group, which resulted in the selection of seven potential targets: tumor-associated calcium signal transducer 2 (TACSTD2), copine-1 (CPNE1), serpin family H member 1 (SERPINH1), stress-induced-phosphoprotein 1 (STIP1), proteasome subunit alpha type-6 (PSMA6), septin 9 (SEPT9) e stanniocalcin 2 (STC2). The selected proteins will be firstly validated by immunohistochemistry, where three of the most promising will be chosen for the further functional assays based on the malignant phenotypes of cancer. With this study, we expect to identify proteins that show prognostic value on OSCC and an important role in the tumor progression, which could reflect on improvement in the disease treatment, in the future. It is important to highlight that, until today, none of the OSCC markers described in the literature are used in the clinic because of the lack of strong evidence.